Amarin Corp Plc (AMRN)

[amarininvestor]

Here is what the judge says

Kurabayashi further reports a statistically significant reduction in Apo B levels in the EPA group of 6.9%. (Id. at 4-5.) With a p-value of < .001, EPA’s effects on Apo B were highly significant. (Id.; see also ECF No. 367 at 737:1-23.) In contrast, Kurabayashi reports a non-statistically significant 1.5% reduction in Apo B levels in the control group. The results reported in Kurabayashi do not suggest any interaction or synergy between EPA and estriol. (ECF No. 367 at 735:21-736:9.) Instead, synergy is usually only seen between drugs that have similar effects, such as two drugs that reduce blood pressure. (Id.) In light of the statistically-significant differential effects reported between the EPA and control groups, a POSA would have attributed the reduction in Apo B to EPA

Now see the below from Kurabayashi’s conclusions (which is supported by the analysis of table-3). Let’s remember that the below is not an opinion, it is a basic conclusion of that paper (a fact), therefore a POSA would not be expected to read the paper and its conclusion in a different way. In my opinion what the judge says: “In light of the statistically-significant differential effects reported between the EPA and control groups” is just an incorrect interpretation of the facts.

"The apolipoprotein B level in the eicosapentaenoic acid group was significantly lower at week 48 compared with the baseline level, but there was no significant difference between the groups".